Blood filtering may save children with sepsis

NCT ID NCT07706413

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This trial investigates whether therapeutic plasma exchange — a procedure that filters the blood to remove harmful substances — can reduce deaths in critically ill children with severe sepsis or septic shock. Participants are randomly assigned to receive either standard sepsis care alone or standard care plus plasma exchange. The study measures survival, organ function, and recovery time in the pediatric intensive care unit.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
therapeutic plasma exchange (a procedure that filters the blood to remove harmful substances)
What this could lead to
If it works, this could offer a way to lower the risk of death and organ failure in children with severe sepsis.
What could go wrong
This is a small, early-stage trial, so results may not apply broadly. Plasma exchange carries risks like bleeding or infection from catheter placement.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEVERE SEPSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Menoufia university hospital, Pediatric intensive care unit

    Shibīn al Kawm, Menoufia Governorate, Egypt

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.